{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:30:51Z","timestamp":1789115451010,"version":"build-2803163510"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.tranon.2026.102833","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T06:41:57Z","timestamp":1779691317000},"page":"102833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The silent pharmacist: Harnessing the gut microbiome to improve therapy in hematologic malignancies"],"prefix":"10.1016","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5481-5617","authenticated-orcid":false,"given":"Amr Ali Mohamed Abdelgawwad","family":"El-Sehrawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-7613","authenticated-orcid":false,"given":"Hamed","family":"Soleimani samarkhazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Supp1","key":"10.1016\/j.tranon.2026.102833_bib0001","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.5152\/FNJN.2023.23046","article-title":"Palliative care in patients with hematological malignancies","volume":"31","author":"Erdal","year":"2023","journal-title":"Florence Nightingale J. Nurs."},{"key":"10.1016\/j.tranon.2026.102833_bib0002","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/978-1-62703-758-7_17","article-title":"Sources of interindividual variability","volume":"1113","author":"Thummel","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.tranon.2026.102833_bib0003","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1146\/annurev.genom.2.1.9","article-title":"Pharmacogenomics: the inherited basis for interindividual differences in drug response","volume":"2","author":"Evans","year":"2001","journal-title":"Annu. Rev. Genom. Hum. Genet."},{"issue":"5","key":"10.1016\/j.tranon.2026.102833_bib0004","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s13238-018-0547-2","article-title":"Pharmacomicrobiomics: a novel route towards personalized medicine?","volume":"9","author":"Doestzada","year":"2018","journal-title":"Protein Cell"},{"issue":"8","key":"10.1016\/j.tranon.2026.102833_bib0005","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1210\/me.2014-1108","article-title":"Minireview: gut microbiota: the neglected endocrine organ","volume":"28","author":"Clarke","year":"2014","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.tranon.2026.102833_bib0006","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1146\/annurev-med-060513-093205","article-title":"The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases","volume":"66","author":"Brown","year":"2015","journal-title":"Annu. Rev. Med."},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0007","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1757-4749-4-16","article-title":"Gut pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes","volume":"4","author":"Saad","year":"2012","journal-title":"Gut. Pathog."},{"key":"10.1016\/j.tranon.2026.102833_bib0008","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1053\/j.gastro.2025.04.025","article-title":"Pharmacomicrobiomics: the role of the gut microbiome in immunomodulation and cancer therapy","volume":"169","author":"Bolte","year":"2025","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.tranon.2026.102833_bib0009","doi-asserted-by":"crossref","first-page":"145","DOI":"10.5045\/br.2023.2023069","article-title":"Fecal microbiota transplantation for steroid-refractory gastrointestinal graft-versus-host disease","volume":"58","author":"Kim","year":"2023","journal-title":"Blood Res."},{"issue":"8","key":"10.1016\/j.tranon.2026.102833_bib0010","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood.2024025366","article-title":"Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy","volume":"145","author":"Prasad","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102833_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1438052","article-title":"Molecular profiling of pre- and post- 5-azacytidine myelodysplastic syndrome samples identifies predictors of response","volume":"14","author":"Gonz\u00e1lez","year":"2024","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.tranon.2026.102833_bib0012","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3390\/biomedicines13071761","article-title":"Microbial crosstalk with therapy: pharmacomicrobiomics in AML-one step closer to personalized medicine","volume":"13","author":"Nowicka","year":"2025","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0013","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3390\/biomedicines12010194","article-title":"Mechanisms and clinical implications of Human gut microbiota-drug interactions in the precision medicine era","volume":"12","author":"Wang","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.tranon.2026.102833_bib0014","article-title":"Probiotics in cancer","volume":"11","author":"Lu","year":"2021","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.tranon.2026.102833_bib0015","article-title":"Probiotics in counteracting the role of neutrophils in cancer metastasis","volume":"9","author":"Mangrolia","year":"2021","journal-title":"Vaccines (Basel) (Basel)"},{"issue":"2","key":"10.1016\/j.tranon.2026.102833_bib0016","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/1535370217743766","article-title":"Gut reactions: how the blood-brain barrier connects the microbiome and the brain","volume":"243","author":"Logsdon","year":"2018","journal-title":"Exp. Biol. Med. (Maywood)"},{"issue":"4","key":"10.1016\/j.tranon.2026.102833_bib0017","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.7150\/ijbs.79430","article-title":"The role of gut microbiota in T cell immunity and immune mediated disorders","volume":"19","author":"Shim","year":"2023","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0018","doi-asserted-by":"crossref","first-page":"8903","DOI":"10.1038\/s41598-023-35097-5","article-title":"Gut microbiota-derived lipid metabolites facilitate regulatory T cell differentiation","volume":"13","author":"Shiratori","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0019","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1186\/s12967-025-06797-5","article-title":"The microbiome in graft-versus-host disease: a tale of two ecosystems","volume":"23","author":"Soleimani Samarkhazan","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.tranon.2026.102833_bib0020","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/1482811","article-title":"Gut microbiome and plasma metabolomic analysis in patients with Myelodysplastic Syndrome","volume":"2022","author":"Jiang","year":"2022","journal-title":"Oxid. Med. Cell Longev."},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0021","doi-asserted-by":"crossref","first-page":"8903","DOI":"10.1038\/s41598-023-35097-5","article-title":"Gut microbiota-derived lipid metabolites facilitate regulatory T cell differentiation","volume":"13","author":"Shiratori","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tranon.2026.102833_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.901559","article-title":"Effects of GLP-1 receptor agonists on biological behavior of colorectal cancer cells by regulating PI3K\/AKT\/mTOR signaling pathway","volume":"13","author":"Tong","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0023","doi-asserted-by":"crossref","first-page":"397","DOI":"10.18063\/cp.397","article-title":"Microbial Architects of malignancy: exploring the gut microbiome\u2019s influence in cancer initiation and progression","volume":"5","author":"Md Fakruddin","year":"2023","journal-title":"Cancer Plus"},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0024","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2022.2127455","article-title":"Myeloid-derived suppressor cells prevent disruption of the gut barrier, preserve microbiota composition, and potentiate immunoregulatory pathways in a rat model of experimental autoimmune encephalomyelitis","volume":"14","author":"Radojevi\u0107","year":"2022","journal-title":"Gut. Microbes"},{"issue":"4","key":"10.1016\/j.tranon.2026.102833_bib0025","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.cell.2016.10.020","article-title":"Linking the Human gut microbiome to inflammatory cytokine production capacity","volume":"167","author":"Schirmer","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.tranon.2026.102833_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2024.102471","article-title":"Microbiome modulation of antigen presentation in tolerance and inflammation","volume":"91","author":"He","year":"2024","journal-title":"Curr. Opin. Immunol"},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0027","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10238-025-01588-0","article-title":"Macrophages in graft-versus-host disease (GVHD): dual roles as therapeutic tools and targets","volume":"25","author":"Raoufi","year":"2025","journal-title":"Clin. Exp. Med."},{"issue":"2","key":"10.1016\/j.tranon.2026.102833_bib0028","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.immuni.2018.12.018","article-title":"The short chain fatty acid butyrate imprints an antimicrobial program in macrophages","volume":"50","author":"Schulthess","year":"2019","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.tranon.2026.102833_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112116","article-title":"The microbiota regulates hematopoietic stem and progenitor cell development by mediating inflammatory signals in the niche","volume":"42","author":"Zhong","year":"2023","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.tranon.2026.102833_bib0030","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.cmet.2015.08.020","article-title":"Microbiota from obese mice regulate hematopoietic stem cell differentiation by altering the bone niche","volume":"22","author":"Luo","year":"2015","journal-title":"Cell Metab."},{"key":"10.1016\/j.tranon.2026.102833_bib0031","article-title":"The impact of gut microbial signals on hematopoietic stem cells and the bone marrow microenvironment","volume":"15","author":"Liu","year":"2024","journal-title":"Front. (Boulder)Front. Immunol."},{"issue":"7706","key":"10.1016\/j.tranon.2026.102833_bib0032","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41586-018-0125-z","article-title":"Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host","volume":"557","author":"Meisel","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0033","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cell.2017.11.034","article-title":"Modulation of myelopoiesis progenitors is an integral component of trained immunity","volume":"172","author":"Mitroulis","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.tranon.2026.102833_bib0034","doi-asserted-by":"crossref","DOI":"10.1038\/srep27634","article-title":"Diet-dependent, microbiota-independent regulation of IL-10-producing lamina propria macrophages in the small intestine","volume":"6","author":"Ochi","year":"2016","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.tranon.2026.102833_bib0035","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.mucimm.2023.02.006","article-title":"The IL-10 receptor inhibits cell extrinsic signals necessary for STAT1-dependent macrophage accumulation during colitis","volume":"16","author":"Patik","year":"2023","journal-title":"Mucosal. Immunol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0036","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10753-023-01911-5","article-title":"SIRT6 Protects against lipopolysaccharide-induced inflammation in Human pulmonary lung microvascular endothelial cells","volume":"47","author":"Wang","year":"2024","journal-title":"Inflammation"},{"issue":"684","key":"10.1016\/j.tranon.2026.102833_bib0037","article-title":"Nutritional support of the gut microbiota protects against lethal complications after allogeneic bone marrow transplantation","volume":"15","author":"Staffas","year":"2023","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.tranon.2026.102833_bib0038","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.leukres.2013.05.005","article-title":"Safety and efficacy of 5-azacytidine treatment in myelodysplastic syndrome patients with moderate and mild renal impairment","volume":"37","author":"Douvali","year":"2013","journal-title":"Leuk. Res."},{"issue":"2","key":"10.1016\/j.tranon.2026.102833_bib0039","first-page":"192","article-title":"Gut microbiota composition correlates with disease severity in myelodysplastic syndrome","volume":"18","author":"Riello","year":"2024","journal-title":"Int. J. Hematol. Oncol. Stem Cell Res."},{"key":"10.1016\/j.tranon.2026.102833_bib0040","article-title":"Gut microbiota in acute leukemia: current evidence and future directions","volume":"13-2022","author":"Zhou","year":"2022","journal-title":"Front. (Boulder)Front. Microbiol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0041","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40364-025-00738-6","article-title":"Unveiling the potential of CLL-1: a promising target for AML therapy","volume":"13","author":"Soleimani Samarkhazan","year":"2025","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0042","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41421-025-00789-x","article-title":"A decrease in flavonifractor plautii and its product, phytosphingosine, predisposes individuals with phlegm-dampness constitution to metabolic disorders","volume":"11","author":"Li","year":"2025","journal-title":"Cell Discov."},{"issue":"2","key":"10.1016\/j.tranon.2026.102833_bib0043","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2263229","article-title":"An analysis of reported cases of hemophagocytic lymphohistiocytosis (HLH) after COVID-19 vaccination","volume":"19","author":"Zhang","year":"2023","journal-title":"Hum. Vaccin. ImmunOther."},{"key":"10.1016\/j.tranon.2026.102833_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113392","article-title":"Unlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies","volume":"144","author":"Sun","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"5","key":"10.1016\/j.tranon.2026.102833_bib0045","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies","volume":"146","author":"Freyer","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0046","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s10194-020-01170-x","article-title":"Gut microbiota regulates neuropathic pain: potential mechanisms and therapeutic strategy","volume":"21","author":"Lin","year":"2020","journal-title":"J. Headache Pain."},{"key":"10.1016\/j.tranon.2026.102833_bib0047","article-title":"Incidence of immune effector cell-associated neurotoxicity among patients treated with CAR T-cell therapy for hematologic malignancies: systematic review and meta-analysis","volume":"15 - 2024","author":"Han","year":"2024","journal-title":"Front. (Boulder)Front. Neurol."},{"issue":"4","key":"10.1016\/j.tranon.2026.102833_bib0048","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10040837","article-title":"The role of fecal microbiota transplantation in the treatment of acute graft-versus-host disease","volume":"10","author":"Bili\u0144ski","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0049","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41409-022-01824-1","article-title":"Safety and efficacy of fecal microbiota transplantation in the treatment of graft-versus-host disease","volume":"58","author":"Qiao","year":"2023","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.tranon.2026.102833_bib0050","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1392831","article-title":"Incidence of immune effector cell-associated neurotoxicity among patients treated with CAR T-cell therapy for hematologic malignancies: systematic review and meta-analysis","volume":"15","author":"Han","year":"2024","journal-title":"Front. Neurol."},{"key":"10.1016\/j.tranon.2026.102833_bib0051","article-title":"Probiotics in cancer","volume":"11 - 2021","author":"Lu","year":"2021","journal-title":"Front. (Boulder)Front. Oncol."},{"issue":"7","key":"10.1016\/j.tranon.2026.102833_bib0052","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3390\/biomedicines13071761","article-title":"Microbial crosstalk with therapy: pharmacomicrobiomics in AML\u2014One step closer to personalized medicine","volume":"13","author":"Nowicka","year":"2025","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0053","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1038\/s41598-021-82726-y","article-title":"Comparison between 16S rRNA and shotgun sequencing data for the taxonomic characterization of the gut microbiota","volume":"11","author":"Durazzi","year":"2021","journal-title":"Sci. Rep."},{"issue":"Pt A","key":"10.1016\/j.tranon.2026.102833_bib0054","article-title":"Fecal 16S rRNA sequencing and multi-compartment metabolomics revealed gut microbiota and metabolites interactions in APP\/PS1 mice","volume":"151","author":"Cheng","year":"2022","journal-title":"Comput. Biol. Med."},{"issue":"12","key":"10.1016\/j.tranon.2026.102833_bib0055","article-title":"Comparison of metagenomics and metatranscriptomics tools: a guide to making the right choice","volume":"13","author":"Terr\u00f3n-Camero","year":"2022","journal-title":"Genes (Basel) (Basel)"},{"issue":"Suppl 1","key":"10.1016\/j.tranon.2026.102833_bib0056","first-page":"5","article-title":"Metagenomics, metatranscriptomics, and metabolomics approaches for microbiome analysis","volume":"12","author":"Aguiar-Pulido","year":"2016","journal-title":"Evol. Bioinform. Online"},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0057","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12934-022-01973-4","article-title":"Machine learning for data integration in human gut microbiome","volume":"21","author":"Li","year":"2022","journal-title":"Microb. Cell Fact."},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0058","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2025.2476570","article-title":"Integrating multi-omics data to reveal the host-microbiota interactome in inflammatory bowel disease","volume":"17","author":"Su","year":"2025","journal-title":"Gut. Microbes"},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0059","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2297860","article-title":"Multi-omic approaches for host-microbiome data integration","volume":"16","author":"Chetty","year":"2024","journal-title":"Gut. Microbes"},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0060","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2021.1941711","article-title":"Investigating causality with fecal microbiota transplantation in rodents: applications, recommendations and pitfalls","volume":"13","author":"Gheorghe","year":"2021","journal-title":"Gut. Microbes"},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0061","doi-asserted-by":"crossref","first-page":"6686","DOI":"10.1038\/s41467-021-26963-9","article-title":"A standardized gnotobiotic mouse model harboring a minimal 15-member mouse gut microbiota recapitulates SOPF\/SPF phenotypes","volume":"12","author":"Darnaud","year":"2021","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.tranon.2026.102833_bib0062","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/febs.17124","article-title":"A guide to germ-free and gnotobiotic mouse technology to study health and disease","volume":"292","author":"Jans","year":"2025","journal-title":"FEBS J."},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0063","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11864-019-0693-7","article-title":"The microbiota in hematologic malignancies","volume":"21","author":"Song","year":"2020","journal-title":"Curr. Treat. Options. Oncol."},{"issue":"9","key":"10.1016\/j.tranon.2026.102833_bib0064","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00203-025-04417-w","article-title":"Therapeutic engineering of the gut microbiome using synthetic biology and metabolic tools: a comprehensive review with E. coli Nissle 1917 as a model case study","volume":"207","author":"Sadhu","year":"2025","journal-title":"Arch. Microbiol."},{"issue":"2","key":"10.1016\/j.tranon.2026.102833_bib0065","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3324\/haematol.2022.282442","article-title":"Advances in next-generation sequencing and emerging technologies for hematologic malignancies","volume":"109","author":"Kwon","year":"2024","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0066","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41409-022-01824-1","article-title":"Safety and efficacy of fecal microbiota transplantation in the treatment of graft-versus-host disease","volume":"58","author":"Qiao","year":"2023","journal-title":"Bone Marrow Transpl."},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0067","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s11033-024-09398-5","article-title":"Next-generation probiotics: the upcoming biotherapeutics","volume":"51","author":"Al-Fakhrany","year":"2024","journal-title":"Mol. Biol. Rep."},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0068","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/1751-7915.13970","article-title":"Next steps after 15 stimulating years of human gut microbiome research","volume":"15","author":"Clavel","year":"2022","journal-title":"Microb. Biotechnol."},{"key":"10.1016\/j.tranon.2026.102833_bib0069","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s41591-025-03615-9","article-title":"Clinical translation of microbiome research","volume":"31","author":"Gilbert","year":"2025","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.tranon.2026.102833_bib0070","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41409-021-01542-0","article-title":"Clinical trials: design, endpoints and interpretation of outcomes","volume":"57","author":"Othus","year":"2022","journal-title":"Bone Marrow Transpl."},{"issue":"9","key":"10.1016\/j.tranon.2026.102833_bib0071","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1056\/NEJMoa1900623","article-title":"Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation","volume":"382","author":"Peled","year":"2020","journal-title":"N. Engl. J. Med. (Baltim.)"},{"issue":"6","key":"10.1016\/j.tranon.2026.102833_bib0072","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41571-018-0006-2","article-title":"The gut microbiota influences anticancer immunosurveillance and general health","volume":"15","author":"Routy","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.tranon.2026.102833_bib0073","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s41591-025-03615-9","article-title":"Clinical translation of microbiome research","volume":"31","author":"Gilbert","year":"2025","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.tranon.2026.102833_bib0074","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41409-021-01542-0","article-title":"Clinical trials: design, endpoints and interpretation of outcomes","volume":"57","author":"Othus","year":"2022","journal-title":"Bone Marrow Transpl."},{"issue":"5","key":"10.1016\/j.tranon.2026.102833_bib0075","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/ni.3400","article-title":"Gut microbiome\u2013derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease","volume":"17","author":"Mathewson","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tranon.2026.102833_bib0076","article-title":"Effects of Litsea cubeba essential oil on growth performance, blood antioxidation, immune function, apparent digestibility of nutrients, and fecal microflora of pigs","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.tranon.2026.102833_bib0077","first-page":"452.e1","article-title":"A randomized clinical trial evaluating lactiplantibacillus plantarum for the prevention of GI aGvHD: a report from the children's oncology group (ACCL1633)","volume":"31","author":"Ladas","year":"2025","journal-title":"Transpl. Cell Ther."},{"key":"10.1016\/j.tranon.2026.102833_bib0078","series-title":"The Effectiveness of Lactobacillus Plantarum (LBP, IND# 17339) in Preventing Acute Graft-Versus-Host Disease (GvHD) in Children Undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)","year":"2017"},{"issue":"7","key":"10.1016\/j.tranon.2026.102833_bib0079","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1182\/bloodadvances.2018017731","article-title":"Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity","volume":"2","author":"DeFilipp","year":"2018","journal-title":"Blood Adv."},{"issue":"556","key":"10.1016\/j.tranon.2026.102833_bib0080","article-title":"Donor fecal microbiota transplantation ameliorates intestinal graft-versus-host disease in allogeneic hematopoietic cell transplant recipients","volume":"12","author":"Donker","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"21","key":"10.1016\/j.tranon.2026.102833_bib0081","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1056\/NEJMoa1910437","article-title":"Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant","volume":"381","author":"DeFilipp","year":"2019","journal-title":"N. Engl. J. Med. (Baltim.)"},{"key":"10.1016\/j.tranon.2026.102833_bib0082","unstructured":"A phase 2 study of fecal microbiota transplantation (FMT) in recipients after allogeneic hematopoietic cell transplantation (HCT). 2018."},{"issue":"5","key":"10.1016\/j.tranon.2026.102833_bib0083","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-068480","article-title":"Faecal microbiota transplantation to prevent complications after allogeneic stem cell transplantation for haematological malignancies: a study protocol for a randomised controlled phase-II trial (the FMT-allo study)","volume":"13","author":"Doug\u00e9","year":"2023","journal-title":"BMJ Open."},{"issue":"8","key":"10.1016\/j.tranon.2026.102833_bib0084","first-page":"484","article-title":"Fecal microbiota transplantation for acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: expanding the horizon into pediatrics","volume":"29","author":"Gray","year":"2023","journal-title":"Transpl. Cell Ther."},{"issue":"16","key":"10.1016\/j.tranon.2026.102833_bib0085","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1182\/blood-2016-05-717652","article-title":"Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut","volume":"128","author":"Kakihana","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0086","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/s41467-025-56375-y","article-title":"Fecal microbiota transplantation to prevent acute graft-versus-host disease: pre-planned interim analysis of donor effect","volume":"16","author":"Reddi","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2026.102833_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2020.100576","article-title":"Fecal microbiota transplantation for patients on antibiotic treatment with C. difficile infection history (GRAFT): study protocol for a phase II, randomized, double-blind, placebo-controlled trial to prevent recurrent C. difficile infections","volume":"18","author":"Kates","year":"2020","journal-title":"Contemp. Clin. Trials Commun."},{"key":"10.1016\/j.tranon.2026.102833_bib0088","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103302","article-title":"Clinical management of Clostridioides difficile infection with faecal microbiota transplantation: a real-world cohort study","volume":"85","author":"Paaske","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"10","key":"10.1016\/j.tranon.2026.102833_bib0089","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1007\/s10096-025-05202-9","article-title":"Fecal microbiota transplant as treatment for recurrent urinary tract infections: a proof-of-concept study","volume":"44","author":"Rico-Caballero","year":"2025","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0090","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s10238-025-01724-w","article-title":"Aptamer-based approaches in leukemia: a paradigm shift in targeted therapy","volume":"25","author":"Bayani","year":"2025","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0091","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s10238-025-01686-z","article-title":"Nanotechnology in leukemia therapy: revolutionizing targeted drug delivery and immune modulation","volume":"25","author":"Bishoyi","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.tranon.2026.102833_bib0092","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114523","article-title":"Acid neutralization and metal-phenolic nanomedicine on-demand release microspheres for reversing cartilage degeneration","volume":"390","author":"Wang","year":"2026","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0093","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1007\/s12672-025-03383-5","article-title":"CRISPR\/Cas technologies in pancreatic cancer research and therapeutics: recent advances and future outlook","volume":"16","author":"Noormohamadi","year":"2025","journal-title":"Discov. Oncol."},{"issue":"475","key":"10.1016\/j.tranon.2026.102833_bib0094","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7975","article-title":"An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans","volume":"11","author":"Kurtz","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"189","key":"10.1016\/j.tranon.2026.102833_bib0095","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.24976\/Discov.Med.202436189.181","article-title":"Gut-liver axis: modulating the Gut microbiota and its metabolic products as a potential therapeutic strategy for the treatment of hepatic ischemia-reperfusion injury","volume":"36","author":"Wang","year":"2024","journal-title":"Discov. Med."},{"issue":"8","key":"10.1016\/j.tranon.2026.102833_bib0096","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood-2016-09-691394","article-title":"The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease","volume":"129","author":"Staffas","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.tranon.2026.102833_bib0097","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jhep.2018.11.005","article-title":"Endpoints and patient stratification in clinical trials for alcoholic hepatitis","volume":"70","author":"Mathurin","year":"2019","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0098","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12943-025-02403-w","article-title":"The tumor microbiome in cancer progression: mechanisms and therapeutic potential","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol. Cancer"},{"issue":"19","key":"10.1016\/j.tranon.2026.102833_bib0099","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251910255","article-title":"Gut microbiota disruption in hematologic cancer therapy: molecular insights and implications for treatment efficacy","volume":"25","author":"Guevara-Ram\u00edrez","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0100","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13020-023-00745-5","article-title":"A novel microbial and hepatic biotransformation-integrated network pharmacology strategy explores the therapeutic mechanisms of bioactive herbal products in neurological diseases: the effects of Astragaloside IV on intracerebral hemorrhage as an example","volume":"18","author":"Hu","year":"2023","journal-title":"Chin. Med."},{"issue":"Pt 2","key":"10.1016\/j.tranon.2026.102833_bib0101","article-title":"Microbiome-transcriptome-histology triad enhances survival risk stratification in multiple cancers","volume":"120","author":"He","year":"2026","journal-title":"Comput. Biol. Chem."},{"key":"10.1016\/j.tranon.2026.102833_bib0102","article-title":"Pharmacomicrobiomics in precision cancer therapy: bench to bedside","volume":"15 - 2024","author":"Le Ngoc","year":"2024","journal-title":"Front. (Boulder)Front. Immunol."},{"issue":"9","key":"10.1016\/j.tranon.2026.102833_bib0103","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/s41423-025-01326-2","article-title":"The gut microbiota in cancer immunity and immunotherapy","volume":"22","author":"Xie","year":"2025","journal-title":"Cell. Mol. Immunol."},{"issue":"181","key":"10.1016\/j.tranon.2026.102833_bib0104","doi-asserted-by":"crossref","first-page":"424","DOI":"10.24976\/Discov.Med.202436181.40","article-title":"Profiling the gut microbiome unraveled signature bacterial groups in autoimmune diabetes, which remain unperturbed by the low ionic strength of the drinking water in NOD mice","volume":"36","author":"Jayaraman","year":"2024","journal-title":"Discov. Med."},{"key":"10.1016\/j.tranon.2026.102833_bib0105","series-title":"Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information","year":"2016"},{"key":"10.1016\/j.tranon.2026.102833_bib0106","series-title":"Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium Difficile Infection Not Responsive to Standard Therapies","year":"2020"},{"key":"10.1016\/j.tranon.2026.102833_bib0107","series-title":"Guideline on Live Biotherapeutic Products","author":"Agency","year":"2020"},{"issue":"5","key":"10.1016\/j.tranon.2026.102833_bib0108","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/15265161.2017.1299240","article-title":"Ethical issues in fecal microbiota transplantation in practice","volume":"17","author":"Ma","year":"2017","journal-title":"Am. J. Bioeth."},{"issue":"3","key":"10.1016\/j.tranon.2026.102833_bib0109","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1080\/20502877.2017.1387386","article-title":"Ethical considerations in microbial therapeutic clinical trials","volume":"23","author":"Woodworth","year":"2017","journal-title":"New Bioeth."},{"issue":"1","key":"10.1016\/j.tranon.2026.102833_bib0110","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41522-025-00678-x","article-title":"Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation","volume":"11","author":"Sun","year":"2025","journal-title":"NPJ. Biofilms. Microbiomes."},{"issue":"3","key":"10.1016\/j.tranon.2026.102833_bib0111","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa2106516","article-title":"SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection","volume":"386","author":"Feuerstadt","year":"2022","journal-title":"N. Engl. J. Med. (Baltim.)"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326001701?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326001701?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:36:11Z","timestamp":1789112171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326001701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":111,"alternative-id":["S1936523326001701"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102833","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The silent pharmacist: Harnessing the gut microbiome to improve therapy in hematologic malignancies","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102833","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102833"}}